Shri Ahimsa Naturals Limited IPO is fully book build issue and total IPO size is ₹73.81 crores. The share offering contains a fresh issue of ₹50.02 crores and offer for sale of 19.99 lakh shares.
The subscription period for the Shri Ahimsa Naturals Limited IPO starts on March 25, 2025, and ends on March 27, 2025. The allotment process is expected to be finalized by March 28, 2025.
The Shri Ahimsa Naturals Limited IPO is scheduled to list on NSE Emerge, with a listing date of April 2, 2025. The price band for the Shri Ahimsa Naturals Limited IPO is ₹113 to ₹119 per share.
Registrar for this IPO is Cameo Corporate Services Limited and lead managers for Shri Ahimsa Naturals Limited IPO are Srujan Alpha Capital Advisors Llp.
Shri Ahimsa Naturals Limited Live GMP Rates day by day
| Date | IPO GMP | Subject to | Last Updated |
|---|---|---|---|
| 28-03-2025 | ₹20 | 16400 | 28-Mar-2025 23:47 |
| 27-03-2025 | ₹24 | 20100 | 27-Mar-2025 23:40 |
| 26-03-2025 | ₹14 | 10900 | 26-Mar-2025 23:41 |
| 25-03-2025 | ₹14 | 10900 | 25-Mar-2025 23:42 |
| 24-03-2025 | ₹12 | 9100 | 24-Mar-2025 15:42 |
| 23-03-2025 | ₹12 | 9100 | 23-Mar-2025 23:46 |
| 22-03-2025 | ₹12 | 9100 | 22-Mar-2025 23:41 |
| 21-03-2025 | ₹5 | 2700 | 21-Mar-2025 23:40 |
| 20-03-2025 | ₹2 | -- | 20-Mar-2025 23:43 |
| 19-03-2025 | ₹2 | -- | 19-Mar-2025 11:17 |
Desclaimer:
Key Details
| Price Band | ₹113 to ₹119 Per Share |
|---|---|
| Lot Size | 1200 Shares |
| Face Value | ₹10 Per Equity Share |
| Total Issue Size | ₹73.81 Crores |
| Fresh Issue | ₹50.02 Crores |
| OFS Issue | ₹23.79 Crores |
| Issue Type | Fresh Issue & OFS |
| Listing At | NSE Emerge |
IPO Schedule
| IPO Open Date | Tuesday, 25 Mar, 2025 |
|---|---|
| IPO Close Date | Thursday, 27 Mar, 2025 |
| IPO Allotment Date | Friday, 28 Mar, 2025 |
| Refund Initiation | Tuesday, 01 Apr, 2025 |
| Share credit in Demat | Tuesday, 01 Apr, 2025 |
| Listing Date | Wednesday, 02 Apr, 2025 |
About Shri Ahimsa Naturals Limited Company
Shri Ahimsa Naturals Ltd, established in 1990, is a manufacturer of Caffeine Anhydrous Natural, Green Coffee Bean Extracts (GCE), and Crude Caffeine, along with trading in herbal extracts. These products cater to the food & beverage, nutraceutical, cosmetics, and pharmaceutical industries due to their various health benefits.
The company processes crude caffeine procured from decaffeination plants to manufacture GCE and Caffeine Anhydrous Natural. Starting in 2022, they began manufacturing Crude Caffeine from tea and coffee waste. A significant portion of their operations is export-focused, serving over 14 countries including the USA, Germany, and South Korea.
Revenue from exports accounted for ₹35.31 crore during the six months ended September 30, 2024, ₹74.64 crore in Fiscal 2024, ₹99.88 crore in Fiscal 2023, and ₹56.34 crore in Fiscal 2022, representing over 86.72%, 95.24%, 95.92% and 97.06% of total revenue from operations, respectively. The company’s manufacturing facility adheres to international standards, complying with ISO and GMP guidelines to ensure product quality. Key leadership is provided by promoters Mr. Nemi Chand Jain, Mr. Amit Jain, Mrs. Sumitra Jain, and Mr. Sumit Jain.
Offer Objectives
The offer includes a fresh issue of 42,03,600 Equity Shares and an Offer for Sale of 19,99,200 Equity Shares by Promoter Selling Shareholders. The company will not receive any proceeds from the Offer for Sale.
The net proceeds from the fresh issue are intended to be utilized for the following:
1. Investment in Wholly-Owned Subsidiary (Shri Ahimsa Healthcare Private Limited - SAHPL): ₹ 3,500 Lakhs (₹35 Crore) for setting up a manufacturing facility at Sawarda, Jaipur, Rajasthan to manufacture Caffeine Anhydrous Natural, Green Coffee Bean Extract and Crude Caffeine.
2. General Corporate Purposes: An amount not exceeding 25% of the Gross Proceeds of the Offer.
The total estimated cost for setting up the manufacturing facility by SAHPL is approximately ₹6,068 Lakhs (₹60.68 Crore). This will be financed through ₹3,500 Lakhs (₹35 Crore) from the IPO proceeds and ₹2,103.71 Lakhs (₹21.0371 Crore) from internal accruals of the Holding Company.
The proposed project's installed capacity will be 700 MT per annum for Caffeine Anhydrous Natural, 300 MT per annum for Green Coffee Bean Extracts, and 63 MT per annum for Crude Caffeine. Commercial production is expected to commence in April 2026. The cost has been determined as per Detailed Project Report (DPR) dated February 01, 2025.
Listing of equity shares is expected to enhance the corporate image, brand visibility, and create a public trading market for the company's equity shares.
